Cann Group (CAN.AX) Aktie Kurs

Cann Group Ltd is primarily active in the cannabis industry.

The main competitors of Cann Group Ltd in the market include other companies involved in the production and distribution of medical cannabis and cannabis-related products. Some significant competitors of Cann Group Ltd may include AusCann Group Holdings Ltd, Althea Group Holdings Ltd, and Little Green Pharma Ltd. These companies operate in the same industry and focus on the cultivation, manufacturing, and sale of medical cannabis products. Cann Group Ltd competes with these companies to gain market share, secure partnerships, and expand their customer base in the rapidly growing cannabis industry.

Cann Group Ltd is an Australian company that specializes in cultivating and producing medical cannabis. Established in 2014, Cann Group was the first to be granted a license to cultivate and research cannabis for medicinal purposes in Australia. With a strong commitment to quality and compliance, the company has built state-of-the-art facilities and established strategic partnerships to expand its operations. Cann Group is dedicated to providing safe and effective cannabis-based products to improve patient outcomes and is at the forefront of the rapidly growing medicinal cannabis industry in Australia.

Cann Group Ltd has achieved several significant milestones in its operations. Firstly, the company became the first Australian business to obtain a license to cultivate medicinal cannabis for research purposes in 2017. This achievement positioned Cann Group Ltd as a pioneer in the country's emerging medicinal cannabis industry. Additionally, the company successfully completed its first commercial cannabis harvest in 2018, marking another important milestone. Furthermore, Cann Group Ltd obtained its crucial Manufacture License in 2019, allowing the company to produce and distribute medicinal cannabis products in Australia. These milestones highlight Cann Group Ltd's commitment to advancing the availability and quality of medicinal cannabis within the country's market.

Cann Group Ltd is primarily present in Australia.

Cann Group Ltd, a leading Australian medicinal cannabis company, embodies a strong set of values and corporate philosophy. The company is committed to producing high-quality medical cannabis products to improve the lives of patients. Cann Group values innovation and sustainability, constantly seeking new ways to enhance their cultivation and manufacturing processes. With a focus on research and development, they aim to continually expand their product offerings and provide effective and safe treatments. Cann Group Ltd prides itself on its dedication to investors, transparency, and regulatory compliance, ensuring a trustworthy and reliable approach to business.

5 analytikere vurderer i øjeblikket Cann Group-aktien: 4 anbefaler køb, 1 hold og 0 salg.

Cann Group Analytikerens Kursmål 2026

Omregnet til den aktuelle valutakurs handles Cann Group-aktien til 0,00 EUR (0,01 AUD).

Cann Group-aktien (CAN.AX) er noteret på 3 børser, herunder: ASX (CAN.AX), Frankfurt (CVJ.F).

Cann Group Ltd is an Australian company specializing in the medical cannabis market. Its business model involves producing, developing, and distributing cannabis for medical use. The company serves various segments, such as the market for human medical products, the veterinary sector, and the recreational and wellness sector. The company is well positioned to benefit from the growing demand for medical cannabis, CBD products for pets, and recreational products.

-omsætningen for Cann Group er 8,56 Mio. AUD. Dette tal er baseret på aktuelle finansielle data og afspejler virksomhedens forretningsydeevne.

-overskuddet for Cann Group er 20,30 Mio. AUD. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.

Pris-til-indtjening-forholdet (P/E) for Cann Group er i øjeblikket 0,36. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af Cann Group-aktien.

Pris-til-salgs-forholdet (P/S) for Cann Group er i øjeblikket 0,85. P/S-forholdet sammenligner markedskapitalisering med årlig omsætning og fungerer som en værdiansættelsesmetrik for Cann Group-aktien.

AlleAktien-kvalitetsscore for Cann Group er 3/10.

ISIN for Cann Group er AU000000CAN2. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.

WKN for Cann Group er A2DSUQ. WKN (Wertpapierkennnummer) er et seks-cifret tysk identifikationsnummer for værdipapirer.

Tickeren for Cann Group er CAN.AX. Tickersymbolet bruges til at handle Cann Group-aktier på børsen.